Genus Capital Management’s Gilead Sciences GILD Stock Holding History

Genus Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.07M	Sell	48,067 -71,213	-60%	-$9.38M	0.6%	51
2026 Q1	$16.6M	Sell	119,280 -16,706	-12%	-$2.34M	1.91%	8
2025 Q4	$16.7M	Sell	135,986 -49,440	-27%	-$6.01M	1.94%	9
2025 Q3	$20.6M	Buy	185,426 +33,390	+22%	+$3.8M	2.39%	4
2025 Q2	$16.9M	Sell	152,036 -31,653	-17%	-$3.37M	2.15%	7
2025 Q1	$20.6M	Buy	+183,689	New	+$19M	2.98%	2
2024 Q2	–	Sell	-26,530	Closed	-$1.94M	–	270
2024 Q1	$1.94M	Buy	+26,530	New	+$2.04M	0.25%	113
2023 Q3	–	Sell	-151,691	Closed	-$11.7M	–	200
2023 Q2	$11.7M	Buy	+151,691	New	+$12.1M	1.72%	12

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Genus Capital Management's GILD Position: Q2 2026 in Review

Genus Capital Management reduced its Gilead Sciences (GILD) stake by 60% in Q2 2026, selling an estimated $9.38M and leaving 48,067 shares worth $6.07M. The position accounts for 0.6% of the portfolio, ranked #51.

Genus Capital Management first reported a position in GILD in Q2 2023 and has held it in 8 quarters since. The position peaked at $20.6M in Q1 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Genus Capital Management held 48,067 shares of Gilead Sciences worth $6.07M as of Q2 2026.
Genus Capital Management sold 71,213 Gilead Sciences shares in Q2 2026, an estimated $9.38M.
Gilead Sciences made up 0.6% of Genus Capital Management's portfolio in Q2 2026, its #51 holding.
Genus Capital Management first reported a position in Gilead Sciences in Q2 2023 and has held it in 8 quarters since.
Genus Capital Management's Gilead Sciences position peaked at $20.6M in Q1 2025.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Genus Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.